Zilhadia
Type 2 diabetes mellitus is one of the most common metabolic diseases, with an increasing prevalence worldwide and a global pandemic. Metformin is the first agent used to lower blood glucose in type 2 diabetic patients. However, using the combination with the sulfonyl urea group, especially glimepiride has recently increased with the benefits of improving patient compliance and cost effectiveness. The purpose of this study was to validate the method of determining metformin/glimepiride fixed dose combinations taken at Pramuka market (the largest drug market in Jakarta) using an inexpensive and easy method, namely UV-Vis spectrophotometry. The maximum wavelength of metformin HCl was 237 and glimepiride was 228 nm. The maximum wavelengths of the two compounds were so close that a simultaneous method was carried out. As per ICH guidelines, the validation indicators measured are linearity, Limit of Detection (LOD), Limit of Quantification (LOQ), accuracy and precision.
分享此文章
English 
Spanish 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 